Acurx Pharmaceuticals, Inc.
Business
Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing ibezapolstat, a novel small-molecule antibiotic targeting Gram-positive bacteria through DNA polymerase IIIC inhibition. Its lead candidate, in Phase 3 development for Clostridioides difficile infection, demonstrated strong clinical cure rates in Phase 2 trials with favorable microbiome preservation. The company also has a pipeline including ACX-375C for systemic infections such as MRSA and vancomycin-resistant Enterococcus. The product is designated for FDA priority review and extended regulatory exclusivity in the U.S. through QIDP and Fast Track designations.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and Development | 2 | 5 | 6 | 5 | 2 | |
| General and Administrative | 6 | 9 | 9 | 7 | 11 | |
| TOTAL OPERATING EXPENSES | 8 | 14 | 15 | 12 | 13 | |
| OPERATING LOSS | −8 | −14 | — | — | — | |
| Interest Income | 125,445 | 20,124 | — | — | — | |
| NET LOSS | −8 | −14 | −15 | −12 | −13 | |
| Basic net loss per common share | −5.32 | −17.45 | −1.15 | −1.12 | −1.49 | |
| Diluted net loss per common share | −5.32 | −17.45 | −1.15 | −1.12 | −1.49 | |
| Weighted average common shares outstanding basic | 1 | 808,168 | 13 | 11 | 9 | |
| Weighted average common shares outstanding diluted | 1 | 808,168 | 13 | 11 | 9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 8 | 4 | 7 | 9 | 13 | |
| Other Receivable | 48,417 | 51,127 | 129,159 | — | — | |
| Prepaid Expenses | 85,018 | 100,123 | 105,776 | 264,955 | 295,304 | |
| TOTAL ASSETS | 8 | 4 | 8 | 9 | 13 | |
| Accounts Payable and Accrued Expenses | 2 | 3 | 3 | 2 | 843,909 | |
| TOTAL CURRENT LIABILITIES | 2 | 3 | 3 | 2 | 843,909 | |
| TOTAL LIABILITIES | 2 | 3 | 3 | 2 | 843,909 | |
| COMMITMENTS AND CONTINGENCIES | — | — | — | — | — | |
| Preferred Stock; $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common Stock; $0.001 par value, 250,000,000 shares authorized, 2,348,113 shares issued and outstanding at December 31, 2025 and 200,000,000 shares authorized, 851,534 shares issued and outstanding at December 31, 2024 | 2,348 | 852 | 14,468 | 11,628 | 10,216 | |
| Additional Paid-In Capital | 81 | 68 | 58 | 46 | 39 | |
| Accumulated Deficit | −75 | −67 | −53 | −39 | −27 | |
| TOTAL SHAREHOLDERS' EQUITY | 5 | 615,121 | 5 | 7 | 12 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 8 | 4 | 8 | 9 | 13 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net Loss | −8 | −14 | −15 | −12 | −13 | |
| Share-Based Compensation | 1 | 3 | 3 | 3 | 5 | |
| Share-Based Payments to Vendors | 322,319 | 833,680 | 559,583 | 430,680 | 2 | |
| Other Receivable | 2,710 | 78,032 | −129,159 | — | — | |
| Prepaid Expenses | 15,105 | 5,653 | 159,179 | 30,349 | −246,695 | |
| Accounts Payable and Accrued Expenses | −408,779 | 200,404 | 980,753 | 1 | 387,978 | |
| Net Cash Used in Operating Activities | −7 | −10 | −10 | −8 | −5 | |
| Reverse Stock Split fractional share adjustment | −1,040 | — | — | — | — | |
| Proceeds from Warrant Inducement, net of issuance costs | 2 | — | — | — | — | |
| Proceeds from Warrant Exercise | 1 | 210,199 | 2 | — | — | |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | 4 | — | — | — | — | |
| Proceeds from 2025 March Registered Direct Offering, net of issuance costs | 889,420 | — | — | — | — | |
| Proceeds from 2025 January Registered Direct Offering, net of issuance costs | 2 | — | — | — | — | |
| Proceeds from At-the-Market Offering, net of issuance costs | — | 6 | — | — | — | |
| Net Cash Provided by Financing Activities | 11 | 7 | 8 | 4 | 15 | |
| Net Increase/(Decrease) in Cash | 4 | −4 | −2 | −4 | 10 | |
| Share-Based Compensation to settle accrued compensation (Note 5) | 413,120 | — | — | — | — | |
| 2025 Equity Line of Credit Purchase Agreement costs (Commitment shares)(Note 4) | 360,000 | — | — | — | — | |
| 2025 Warrant Inducement Financing costs (Note 4) | 5 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Acurx Pharmaceuticals, Inc.'s CIK number?
Acurx Pharmaceuticals, Inc.'s SEC CIK number is 0001736243 (1736243). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Acurx Pharmaceuticals, Inc.'s SEC filings?
All of Acurx Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Acurx Pharmaceuticals, Inc. last report earnings?
Acurx Pharmaceuticals, Inc. (ACXP) most recently filed an earnings 8-K with the SEC on May 13, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-25-047566). This is Acurx Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Acurx Pharmaceuticals, Inc.'s most recent earnings 8-K?
Acurx Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2025 under accession 0001104659-25-047566. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Acurx Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →